Mycobacterium Xenopi Clinical Presentation

  • Author: Mansoor Arif, MD, MBBS; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Apr 24, 2012
 

History

Infection with M xenopi may result in pulmonary infection, usually in older adults with COPD, in patients who are immunocompromised with disseminated disease, or in patients with extrapulmonary disease involving the lymphatic system, skin, bones, or joints.[3, 4] Onset of symptoms is insidious, and the infection may progress slowly or increase and decrease over the course of months or years.

Presenting symptoms

  • Chronic productive cough (90%)
  • Dyspnea (80%)
  • Constitutional symptoms such as weakness, malaise, and weight loss (90%)
  • Hemoptysis (20%)
  • Night sweats (20%)
  • Fever (10%)

Presenting symptoms of immunocompromised patients with disseminated disease

  • Prolonged febrile illness (95%)
  • Wasting syndrome (95%)

Possible presenting symptoms of patients with HIV infection

  • Advanced disease
  • Low CD4+ cell counts (< 50/µL)
  • Prior AIDS-defining illness
Next

Physical

Physical findings relate to underlying long-term illness and are not specific for M xenopi infection. More than 95% of patients have abnormal lung findings.

Previous
Next

Causes

Predisposing factors include the following:

  • Preexisting lung disease (eg, COPD, bronchiectasis)
  • Pulmonary or extrapulmonary malignancy
  • Alcoholism
  • Diabetes mellitus
  • Immunocompromised state (eg, HIV infection, AIDS)
  • Exposure via inhalation of aerosolized water infected with M xenopi or contact with infected water droplets

Sirolimus therapy inhibits interleukin 12–induced proliferation of activated T lymphocytes and may be a risk factor.

Previous
 
 
Contributor Information and Disclosures
Author

Mansoor Arif, MD, MBBS  Research Associate, Department of Research, Indus Hospital, Pakistan

Disclosure: Nothing to disclose.

Coauthor(s)

Syed Faisal Mahmood, MBBS  Assistant Professor of Infectious Diseases, Department of Medicine, Aga Khan University Hospital, Pakistan

Disclosure: Nothing to disclose.

Specialty Editor Board

Wesley W Emmons, MD, FACP  Assistant Professor, Department of Medicine, Thomas Jefferson University; Consulting Staff, Infectious Diseases Section, Department of Internal Medicine, Christiana Care, Newark, DE

Wesley W Emmons, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and International AIDS Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Aaron Glatt, MD  Professor of Clinical Medicine, New York Medical College; President and CEO, Former Chief Medical Officer, Departments of Medicine and Infectious Diseases, St Joseph Hospital (formerly New Island Hospital)

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Larry I Lutwick, MD, Martin Backer, MD, Sailaja Kolli, MD, and Klaus-Dieter Lessnau, MD, FCCP, to the development and writing of this article.

References
  1. Sebakova H, Kozisek F, Mudra R, Kaustova J, Fiedorova M, Hanslikova D, et al. Incidence of nontuberculous mycobacteria in four hot water systems using various types of disinfection. Can J Microbiol. Nov 2008;54(11):891-8. [Medline].

  2. Hussein Z, Landt O, Wirths B, Wellinghausen N. Detection of non-tuberculous mycobacteria in hospital water by culture and molecular methods. Int J Med Microbiol. Apr 2009;299(4):281-90. [Medline].

  3. Salmon JH, Direz G, Ziza JM, Desplaces N, Brochot P, Eschard JP. Discitis and sacroiliitis diagnosed 15years after iatrogenic Mycobacterium xenopi inoculation. Joint Bone Spine. Mar 9 2012;[Medline].

  4. Portillo ME, Sánchez F, Vicente E, Salvadó M. [Trochanteric bursitis due to Mycobacterium xenopi in a patient with pharmacological immunosuppression]. Enferm Infecc Microbiol Clin. May 2011;29(5):399-401. [Medline].

  5. Alvarez-Uria G, Falcó V, Martín-Casabona N, Crespo M, Villar Del Saz S, Curran A, et al. Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?. Int J STD AIDS. Mar 2009;20(3):193-5. [Medline].

  6. De Lorenzi D, Solano-Gallego L. Tracheal granuloma because of infection with a novel mycobacterial species in an old FIV-positive cat. J Small Anim Pract. Mar 2009;50(3):143-6. [Medline].

  7. Al Jarad N, Demertzis P, Jones DJ, et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax. Feb 1996;51(2):137-9. [Medline].

  8. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. Aug 1997;156(2 Pt 2):S1-25. [Medline].

  9. Andrejak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. Apr 2009;64(4):291-6. [Medline].

  10. Andréjak C, Lescure FX, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. Apr 2009;64(4):291-6. [Medline].

  11. Ausina V, Barrio J, Luquin M, et al. Mycobacterium xenopi infections in the acquired immunodeficiency syndrome. Ann Intern Med. Dec 1 1988;109(11):927-8. [Medline].

  12. Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax. May 1984;39(5):376-82. [Medline].

  13. Bennett SN, Peterson DE, Johnson DR, et al. Bronchoscopy-associated Mycobacterium xenopi pseudoinfections. Am J Respir Crit Care Med. Jul 1994;150(1):245-50. [Medline].

  14. Bishburg E, Zucker MJ, Baran DA, Arroyo LH. Mycobacterium xenopi infection after heart transplantation: an unreported pathogen. Transplant Proc. Nov 2004;36(9):2834-6. [Medline].

  15. Chen F, Sethi G, Goldin R, et al. Concurrent granulomatous Pneumocystis carinii and Mycobacterium xenopi pneumonia: an unusual manifestation of HIV immune reconstitution disease. Thorax. Nov 2004;59(11):997-9. [Medline].

  16. Costrini AM, Mahler DA, Gross WM, et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. Jan 1981;123(1):104-9. [Medline].

  17. David E. Griffith, Timothy Aksamit, Barbara A. Brown-Elliott, Antonino Catanzaro, Charles Daley, Fred Gordin, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Available at http://www.thoracic.org/statements/resources/mtpi/nontuberculous-mycobacterial-diseases.pdf.

  18. el-Helou P, Rachlis A, Fong I, et al. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. Clin Infect Dis. Aug 1997;25(2):206-10. [Medline].

  19. El-Solh AA, Nopper J, Abdul-Khoudoud MR, et al. Clinical and radiographic manifestations of uncommon pulmonary nontuberculous mycobacterial disease in AIDS patients. Chest. Jul 1998;114(1):138-45. [Medline].

  20. Eng RH, Forrester C, Smith SM, Sobel H. Mycobacterium xenopi infection in a patient with acquired immunodeficiency syndrome. Chest. Jul 1984;86(1):145-7. [Medline].

  21. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. Mar 2001;56(3):167-72. [Medline].

  22. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. May 1993;147(5):1271-8. [Medline].

  23. Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc. Jan 1999;74(1):45-51. [Medline].

  24. Ibarra MR, Algarabel PA, Marquina C, Arnaudas JI, del Moral A, Pareti L. Magnetic phase diagram and anisotropy of pseudoternary (ErxDy1-x)2Fe14B compounds. Phys Rev B Condens Matter. Apr 1 1989;39(10):7081-7088. [Medline].

  25. Jiva TM, Jacoby HM, Weymouth LA, et al. Mycobacterium xenopi: innocent bystander or emerging pathogen?. Clin Infect Dis. Feb 1997;24(2):226-32. [Medline].

  26. Koizumi JH, Sommers HM. Mycobacterium xenopi and pulmonary disease. Am J Clin Pathol. Jun 1980;73(6):826-30. [Medline].

  27. Kotloff RM. Infection caused by nontuberculous mycobacteria: clinical aspects. Semin Roentgenol. Apr 1993;28(2):131-8. [Medline].

  28. Lavy A, Rusu R, Mates A. Mycobacterium xenopi, a potential human pathogen. Isr J Med Sci. Nov 1992;28(11):772-5. [Medline].

  29. Maimon N, Brunton J, Chan AK, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax. Aug 2007;62(8):739-40. [Medline].

  30. Majoor CJ, Schreurs AJ, Weers-Pothoff G. Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. Thorax. Jul 2004;59(7):631-2. [Medline].

  31. Martin-Penagos L, Rodrigo E, Ruiz JC, et al. Lung cavitation due to Mycobacterium xenopi in a renal transplant recipient. Transpl Infect Dis. Jun 2009;11(3):249-52. [Medline].

  32. Massachusetts General Hospital. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-1989. A 58-year-old man with cavitary lung disease. N Engl J Med. Apr 27 1989;320(17):1130-9. [Medline].

  33. Matsui Y, Tamura A, Nagayama N, Akashi S, Araki K, Kimura H, et al. [Review of pulmonary Mycobacterium xenopi infection cases: 11 cases of our own and 18 other cases reported in Japan]. Kekkaku. Aug 2010;85(8):647-53. [Medline].

  34. Meybeck A, Fortin C, Abgrall S, et al. Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature. J Clin Microbiol. Mar 2005;43(3):1465-6. [Medline].

  35. Miller WC, Perkins MD, Richardson WJ, Sexton DJ. Pott's disease caused by Mycobacterium xenopi: case report and review. Clin Infect Dis. Dec 1994;19(6):1024-8. [Medline].

  36. Miller WT, Miller WT. Pulmonary infections with atypical mycobacteria in the normal host. Semin Roentgenol. Apr 1993;28(2):139-49. [Medline].

  37. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. May 1987;135(5):1007-14. [Medline].

  38. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. Mar 15 2003;167(6):835-40. [Medline].

  39. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. Mar 15 2003;167(6):828-34. [Medline].

  40. Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol. May-Jun 1995;13(3):207-22. [Medline].

  41. Primm TP, Lucero CA, Falkinham JO 3rd. Health impacts of environmental mycobacteria. Clin Microbiol Rev. Jan 2004;17(1):98-106. [Medline]. [Full Text].

  42. Schmitt H, Schnitzler N, Riehl J, et al. Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin. Clin Infect Dis. Jul 1999;29(1):120-4. [Medline].

  43. Schwabacher H. A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man. J Hyg (Lond). Mar 1959;57(1):57-67. [Medline].

  44. Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis. Jul 1992;15(1):161-2. [Medline].

  45. Simor AE, Salit IE, Vellend H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis. Mar 1984;129(3):435-8. [Medline].

  46. Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax. May 1983;38(5):373-7. [Medline].

  47. Sniadack DH, Ostroff SM, Karlix MA, et al. A nosocomial pseudo-outbreak of Mycobacterium xenopi due to a contaminated potable water supply: lessons in prevention. Infect Control Hosp Epidemiol. Nov 1993;14(11):636-41. [Medline].

  48. Thaunat O, Morelon E, Stern M, et al. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transpl Infect Dis. Dec 2004;6(4):179-82. [Medline].

  49. Torkko P, Suomalainen S, Iivanainen E, Suutari M, Tortoli E, Paulin L. Mycobacterium xenopi and related organisms isolated from stream waters in Finland and description of Mycobacterium botniense sp. nov. Int J Syst Evol Microbiol. Jan 2000;50 Pt 1:283-9. [Medline].

  50. van Ingen J, Boeree MJ, de Lange WC, Hoefsloot W, Bendien SA, Magis-Escurra C. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis. Mar 2008;14(3):385-9. [Medline].

  51. Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. Oct 2009;13(10):1210-8. [Medline].

  52. Wang HX, Yue J, Han M, Yang JH, Gao RL, Jing LJ. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008. Chin Med J (Engl). Jan 20 2010;123(2):184-7. [Medline].

  53. Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore). Mar 1994;73(2):103-9. [Medline].

  54. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis. Jul 1992;15(1):1-10. [Medline].

  55. Zurawski CA, Cage GD, Rimland D, Blumberg HM. Pneumonia and bacteremia due to Mycobacterium celatum masquerading as Mycobacterium xenopi in patients with AIDS: an underdiagnosed problem?. Clin Infect Dis. Feb 1997;24(2):140-3. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.